Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib vs Best Available Therapy in TKI-Resistant/Intolerant CML-CP
NCT04126681Phase 2Completed
- Sponsor
- Ascentage Pharma
- Start
- Oct 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olverembatinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Ascentage Pharma. Primary endpoint: Event Free Survival at 24 months. Started Oct 2019; status: completed.
02
Drugs
olverembatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04126681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126681.